David Bearss

Company: Halia Therapeutics

Job title: Chief Executive Officer & President

Seminars:

First in Human Dosing of HT-6184, a Novel Allosteric NEK7 Inhibitor Targeting NLRP3 Assembly & Function 12:00 pm

Explore how targeting the ability of Nek7 to bind to NLRP3 blocks and activation and promotes disassembly of the NLRP3 Inflammasome Review how HT-6184 potently blocks NLRP3 activity and function Evaluate data on the PK and PD of HT-6184 in the firstin- human trial that will be presentedRead more

day: Day 2 - Track B - Morning